Find a Trial
Trial Results
2 protocol(s) meet the specified criteria
CTO-208887OPEN TO ACCRUAL
A Phase I/II Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM5
CTO-R5458-ONC-1826OPEN TO ACCRUAL
A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
